Skimmin
Based on 1 publication(s) in Google Scholar
Skimmin (Umbelliferone glucoside) is a major pharmacologically active and orally active molecule present in Hydrangea paniculata, a medical herb used in traditional Chinese medicine as an anti-inflammatory agent. Skimmin has renal protective activity. Skimmin can improve creatinine clearance, and reduce plasma creatinine, and kidney injuries. Skimmin has good anti-amoebic activity against the HM1:IMMS strain of Entamoeba histolytica. Skimmin has anti-cancer and neuroprotective activities. Skimmin reduces cardiac fibrosis as well as decreasing TNF-α, IL-6, IL1β, and TGFβ1 in cardiac tissues. Skimmin can be studied in research for diabetes and diabetes-related diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.64%
- CAS No.: 93-39-0
- Formule: C15H16O8
- Masse moléculaire:324.28
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Skimmin
MoreVoir tous les produits spécifiques à Isoform TNF Receptor
MoreVoir tous les produits spécifiques à Isoform Parasite
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SK-OV-3 | IC50 |
>100 μM
Compound: 3
|
Antiproliferative activity against human SK-OV-3 cells measured after 21 hrs by MTT assay
Antiproliferative activity against human SK-OV-3 cells measured after 21 hrs by MTT assay
|
[PMID: 38340509] |
Skimmin (15-30 mg/kg, i.g., 16 w) showed a certain effect on decreasing blood glucose in male SD rats[3].
Skimmin (7.5-30 mg/kg, p.o., 17 w) results in significantly less severe sclerosis in glomerulus segments especially at 15 mg/kg and 30 mg/kg dose in Wistar rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female SD rats, 10 weeks old, (160-180 g)[1]
-
Dosage:15 or 30 mg/kg
-
Administration:Intragastric injection (i.g.) daily from days 37 to 66
-
Result:Reduced BUN whilst increased Ucr and urinary creatinine (Ccr) with 30 mg/kg dose.
Significantly reduced C-BSA-induced morphological changes including incidences of glomerular hypercellarity, glomerular basement membrane thickening or mesangial proliferation, and tubulointerstitial injuries.
Led to significantly less deposits of immune complexes in the mesangial areas and along the capillary walls.
Reduced the IgG positive staining area by 41% compared to model group.
Decreased the expression of IL-1β and IL-6 in glomeruli dose-dependently.
Reduced the CD20 mature B cell infiltration significantly.
-
Animal Model:Male Sprague Dawley rats (160-180 g, 6-8 w) with Streptozotocin (HY-13753) (60 mg/kg, i.p.)-induced type 1 diabetes mellitus[3]
-
Dosage:15 or 30 mg/kg
-
Administration:Intragastric injection (i.g.) daily for 16 w
-
Result:Lightly reduced the HR, SBP, DBP, and MAP.
Significantly improved cardiac function in diabetic rats dose dependently.
Significantly reduced the heart NO and malondialdehyde (MDA) concentration and increased GSH concentration in the heart.
Increased the enzyme activity of SOD and CAT in the heart tissues.
Showed anti-inflammatory activity by decreasing TNF-α, IL-6, IL1β, and TGFβ1 in the heart tissues from DCM rats.
Exerted a cardiac protective effect and inhibited the NLRP3 pathway in diabetic hearts by decreasing NLRP3, caspase-1, and IL-1β.
Reduced the P62 protein level in the heart tissues.
-
Animal Model:Adult male Wistar rats (180-200 g) with Streptozotocin (60 mg/kg)-induced diabetic nephropathy[4]
-
Dosage:7.5, 10, 30 mg/kg
-
Administration:Oral gavage (p.o.) for 17 weeks
-
Result:Reduced the incidence of tubule vacuolar degeneration and severity level.
Decreased TGF-β1 expression on mRNA level in the renal tissues dose dependently.
Chemical Information
-
CAS No. 93-39-0
-
Appearance Solid
-
Masse moléculaire 324.28
-
Formule C15H16O8
-
Color White to off-white
-
SMILES
O=C1C=CC2=CC=C(O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)O)O)C=C2O1
-
Synonyms
Umbelliferone glucoside
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvant et solubilité
DMSO : 100 mg/mL (308.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Zhang S, et al. Skimmin, a Coumarin from Hydrangea paniculata, Slows down the Progression of Membranous Glomerulonephritis by Anti-Inflammatory Effects and Inhibiting Immune Complex Deposition. Evid Based Complement Alternat Med. 2013;2013:819296. [Content Brief]
[2]. Lou, Y., et al., (2020). Determination and pharmacokinetic study of skimmin by UHPLC-MS/MS in rat plasma. Journal of pharmaceutical and biomedical analysis, 179, 112969. [Content Brief]
[3]. Liang, R. K., et al., (2021). Skimmin protects diabetic cardiomyopathy in streptozotocin-induced diabetic rats. The Kaohsiung journal of medical sciences, 37(2), 136–144. [Content Brief]
[4]. Zhang, S., et al., (2012). Skimmin, a coumarin, suppresses the streptozotocin-induced diabetic nephropathy in wistar rats. European journal of pharmacology, 692(1-3), 78–83. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0838 mL | 15.4188 mL | 30.8375 mL | 77.0939 mL |
| 5 mM | 0.6168 mL | 3.0838 mL | 6.1675 mL | 15.4188 mL | |
| 10 mM | 0.3084 mL | 1.5419 mL | 3.0838 mL | 7.7094 mL | |
| 15 mM | 0.2056 mL | 1.0279 mL | 2.0558 mL | 5.1396 mL | |
| 20 mM | 0.1542 mL | 0.7709 mL | 1.5419 mL | 3.8547 mL | |
| 25 mM | 0.1234 mL | 0.6168 mL | 1.2335 mL | 3.0838 mL | |
| 30 mM | 0.1028 mL | 0.5140 mL | 1.0279 mL | 2.5698 mL | |
| 40 mM | 0.0771 mL | 0.3855 mL | 0.7709 mL | 1.9273 mL | |
| 50 mM | 0.0617 mL | 0.3084 mL | 0.6168 mL | 1.5419 mL | |
| 60 mM | 0.0514 mL | 0.2570 mL | 0.5140 mL | 1.2849 mL | |
| 80 mM | 0.0385 mL | 0.1927 mL | 0.3855 mL | 0.9637 mL | |
| 100 mM | 0.0308 mL | 0.1542 mL | 0.3084 mL | 0.7709 mL |
Skimmin Related Classifications
HY-N2263 Related Classifications
Powered by Bioz